VTGN logo

VTGN VistaGen Therapeutics, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$0.16
-0.02 (-12.33%)

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neuroactive nasal spray currently in Phase III trials for the rapid treatment of anxiety in adults exper…

Market Cap: $7.56Mwww.vistagen.com

Price

No data yet.

Social Signal Score

51
5d
—
30d
50
1 mentions
—
60d
48
4 mentions
—
90d
55
6 mentions
—
news: 6

Analyst Ratings

7 analysts
Holdconsensus
Strong Buy 0Buy 3Hold 4Sell 0Strong Sell 0
Avg price target$0.95+480.7%
Low $0.9Median $0.95High $1
Current Consensus

Revenue

$138.0K-88.96%
$-892.5K$-103.0K$686.5K$1.48M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-1.74
$-1.78–$-1.68
2 analysts
FY2026
$-1.78
$-1.83–$-1.72
3 analysts
FY2027
$-1.28
$-1.35–$-1.21
1 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Shawn K. Singh
Sector
Healthcare
Industry
Biotechnology
Employees
41
Beta
0.39
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
-37.00
www.vistagen.com